Key Documents

View All Documentation

855855

Cytosine β-D-arabinofuranoside hydrochloride

Name: Cytosine β-<SC>D</SC>-arabinofuranoside hydrochloride
Brand: ALDRICH

98%

Synonym(s):

1-(β-D-Arabinofuranosyl)cytosine hydrochloride, Ara-C hydrochloride, Arabinocytidine hydrochloride, Arabinosylcytosine hydrochloride, Cytarabine hydrochloride, Cytosine arabinoside hydrochloride

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₉H₁₃N₃O₅ · HCl

CAS Number:

69-74-9

Molecular Weight:

279.68

UNSPSC Code:

12352100

MDL number:

MFCD00012839

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

assay

98%

optical activity

[α]25/D +130°, c = 1 in H₂O

mp

197-198 °C (lit.)

SMILES string

Cl[H].NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

1S/C9H13N3O5.ClH/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8;/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16);1H/t4-,6-,7+,8-;/m1./s1

InChI key

KCURWTAZOZXKSJ-JBMRGDGGSA-N

Description

Biochem/physiol Actions

Ara-C is phosphorylated to Ara-CTP and is incorporatee into DNA. It inhibits DNA replication by forming cleavage complexes with topoisomerase I resulting in DNA fragmentation, and ultimately induces apoptosis via the PKC signaling pathway. Does not inhibit RNA synthesis. Anti-leukemia agent.

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.

Julie M Vose et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(13), 1662-1668 (2013-03-13)

This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients with chemotherapy-sensitive persistent or relapsed DLBCL were

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

Sergio Amadori et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(35), 4424-4430 (2013-10-16)

This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML). Patients (n = 472) age 61 to 75 years were randomly assigned to induction

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.

Jorge Cortes et al.

The Lancet. Oncology, 14(4), 354-362 (2013-03-05)

Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elderly patients with relapsed or refractory acute myeloid leukaemia (AML). We aimed to compare two dosing regimens of tosedostat. In this randomised phase

View All Related Papers